NewEdge Advisors LLC Acquires 5,761 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• NewEdge Advisors increased its IDEXX Laboratories position by 60.9% in the first quarter, acquiring 5,761 additional shares for a total of 15,221 shares valued at approximately $8.55 million.
• IDEXX reported quarterly EPS of $4.27, exceeding the $3.94 consensus estimate, while revenue reached $1.22 billion, up 9.7% year over year. The company maintained fiscal 2026 EPS guidance of $14.69–$14.94.
• Analysts maintain a generally positive outlook, with six Buy and four Hold ratings, an overall “Moderate Buy” consensus, and an average price target of $756 versus the stock’s reported $586.67 price.

NewEdge Advisors LLC lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 60.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,221 shares of the company's stock after buying an additional 5,761 shares during the quarter. NewEdge Advisors LLC's holdings in IDEXX Laboratories were worth $8,552,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. KBC Group NV raised its position in shares of IDEXX Laboratories by 76.9% in the 4th quarter. KBC Group NV now owns 309,380 shares of the company's stock valued at $209,305,000 after acquiring an additional 134,493 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in IDEXX Laboratories by 4.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 209,106 shares of the company's stock valued at $141,466,000 after purchasing an additional 8,626 shares during the period. Elyxium Wealth LLC bought a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $3,666,459,000. NewEdge Wealth LLC increased its stake in IDEXX Laboratories by 122.3% in the fourth quarter. NewEdge Wealth LLC now owns 6,597 shares of the company's stock valued at $4,463,000 after purchasing an additional 3,629 shares in the last quarter. Finally, Prospera Financial Services Inc acquired a new stake in IDEXX Laboratories in the fourth quarter worth $4,188,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

IDXX opened at $586.67 on Monday. The stock has a market capitalization of $46.22 billion, a P/E ratio of 41.26, a P/E/G ratio of 3.18 and a beta of 1.54. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98. The firm's fifty day simple moving average is $559.73 and its 200 day simple moving average is $584.88. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company's revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on IDXX shares. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. UBS Group lifted their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Weiss Ratings raised IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research note on Wednesday, July 29th. Finally, Citigroup increased their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average price target of $756.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source